Cerevance Stock

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.

Sign up today and learn more about Cerevance Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Cerevance Stock

Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.

Funding History

December 2016$21.5M
May 2017$5.0M
April 2020$65.0M
February 2023$51.0M

Management

Executive Director of Regulatory Affairs

Michelle Charles

Board Observer

Ben Robbins

CSO & Co-Founder

Mark Carlton

Board Member

Matthias Kleinz

VP of Drug Discovery

Roland Burli

Board Member

Laurence Barker

Vice President of Neuroscience

Lee Dawson

Board Member

Jason Lettmann

Co-founder and Board Chair

Brad Margus

SVP of Clinical & Translational Medicine

David Margolin

CFO

Robert Middlebrook

Chief Scientific Advisor

Nathaniel Heintz

Chief Executive Officer

Craig Thompson

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo